dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorMiguel, Tarciso Tadeu
dc.creatorNunes-de-Souza, Ricardo Luiz
dc.date2014-05-20T15:34:36Z
dc.date2016-10-25T18:11:02Z
dc.date2014-05-20T15:34:36Z
dc.date2016-10-25T18:11:02Z
dc.date2011-08-01
dc.date.accessioned2017-04-06T00:36:58Z
dc.date.available2017-04-06T00:36:58Z
dc.identifierHormones and Behavior. San Diego: Academic Press Inc. Elsevier B.V., v. 60, n. 3, p. 292-300, 2011.
dc.identifier0018-506X
dc.identifierhttp://hdl.handle.net/11449/42597
dc.identifierhttp://acervodigital.unesp.br/handle/11449/42597
dc.identifier10.1016/j.yhbeh.2011.06.004
dc.identifierWOS:000293316000010
dc.identifierWOS000293316000010.pdf
dc.identifierhttp://dx.doi.org/10.1016/j.yhbeh.2011.06.004
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/885244
dc.descriptionChemical or electrical stimulation of the dorsal portion of the midbrain periaqueductal gray (dPAG) produces anxiogenic and antinociceptive effects. In rats, chemical stimulation of dPAG by local infusion of the neuropeptide corticotropin-releasing factor (CRF) provokes anxiogenic effects in the elevated plus-maze test (EPM). CRF also produces antinociception when injected intracerebroventricularly in rats, however it remains unclear whether this response is also observed following CRF injection into the dPAG in mice. Yet, given that there are CRF1 and CRF2 receptor subtypes within the PAG, it is important to show in which receptor subtypes CRF exert its anxiogenic and antinociceptive effects in the dPAG. Here, we investigated the role of these receptors in the anxiogenic (assessed in the EPM) and antinociceptive (assessed by the Formalin test: 2.5% formalin injection into the right hind paw) effects following intra-dPAG infusion of CRF in mice. The results show that intra-dPAG injections of CRF (75 pmol/0.1 mu l and 150 pmol/0.2 mu l) produced dose-dependent anxiogenic and antinociceptive effects. In addition, local infusion of NBI 27914 (5-chloro-4-(N-(cyclopropyl) methyl-N-propylamino)-2-methyl-6-(2,4,6-trichlorophenyl)-aminopyridine; 2 nmo1/0.2 pl), a CRF1 receptor antagonist, completely blocked both the anxiogenic and antinociceptive effects induced by local infusion of CRF, while that of antisauvagine 30 (ASV30; 1 nmol/0.2 mu l), a CRF2 receptor antagonist, did not alter the CRF effects. Present results are suggestive that CRF1 (but not CRF2) receptors play a crucial role in the anxiogenic and antinociceptive effects induced by CRF in the dPAG in mice. (C) 2011 Elsevier B.V. All rights reserved.
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.languageeng
dc.publisherAcademic Press Inc. Elsevier B.V.
dc.relationHormones and Behavior
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAnxiety
dc.subjectAntinociception
dc.subjectCRF1 and CRF2 receptors
dc.subjectPeriaqueductal gray
dc.subjectElevated plus-maze
dc.subjectMice
dc.titleAnxiogenic and antinociceptive effects induced by corticotropin-releasing factor (CRF) injections into the periaqueductal gray are modulated by CRF1 receptor in mice
dc.typeOtro


Este ítem pertenece a la siguiente institución